Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

By afschroeder • October 24, 2025

Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025 Oct 21:S1556-0864(25)02856-4. doi: 10.1016/j.jtho.2025.10.009. Epub ahead of print. PMID: 41130408.

Tags: Cardiology/Epi, EGFR, MET (min 3), NSCLC, Osimertinib, Publications, Savolitinib (max 5)

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]

Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population

Spencer-Bonilla G, Fan J, Cheng P, Din N, Rodriguez F, Davies M, Papas MA, Huang J, Venditto J, Witteles RM, Heidenreich P, Alexander K, Sandhu[...]